Exact Sciences (company)

Dak Prescott Joins Ryan Reynolds’ Maximum Effort and the Colorectal Cancer Alliance to ‘LEAD FROM BEHIND’

Retrieved on: 
Friday, December 8, 2023

NFL quarterback Dak Prescott of the Dallas Cowboys is teaming up with the nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance), and Ryan Reynolds’ creative agency, Maximum Effort, to LEAD FROM BEHIND.

Key Points: 
  • NFL quarterback Dak Prescott of the Dallas Cowboys is teaming up with the nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance), and Ryan Reynolds’ creative agency, Maximum Effort, to LEAD FROM BEHIND.
  • “Losing my mother to colon cancer was devastating, and no one should have to go through that,” said Prescott.
  • “I’d like to thank Dak for joining Rob McElhenney, Terry Crews, and me in helping raise awareness for dropping your drawers,” said Maximum Effort Co-founder Ryan Reynolds.
  • "The mission of the Alliance is to end colorectal cancer in our lifetime,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

Exact Sciences Awards Grants to 23 Organizations Focused on Increasing Colorectal Cancer Screenings

Retrieved on: 
Thursday, December 7, 2023

Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making healthcare more accessible, with a focus on medically underserved populations.

Key Points: 
  • Grant recipients are committed to improving colorectal cancer (CRC) screening rates and making healthcare more accessible, with a focus on medically underserved populations.
  • Exact Sciences' FOCUS Program provides grant funding to community organizations, health foundations, public health organizations, and advocacy groups working to increase access to CRC screening.
  • Exact Sciences developed Cologuard®, the first and only FDA-approved, noninvasive, multi-target, stool-based DNA screening test that people can use at home.
  • Since making the test available in 2014, Exact Sciences has delivered more than 13 million Cologuard results to patients.

Exact Sciences Files Patent Infringement Lawsuit Against Geneoscopy

Retrieved on: 
Friday, November 17, 2023

MADISON, Wis., Nov. 17, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware. The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or offering for sale Geneoscopy's ColoSense product or otherwise infringing on Exact Sciences' U.S. Patent No. 11,634,781 ("the '781 Patent"). The filed complaint can be accessed on the Exact Sciences' website. 

Key Points: 
  • The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or offering for sale Geneoscopy's ColoSense product or otherwise infringing on Exact Sciences' U.S. Patent No.
  • Exact Sciences utilizes the patented '781 technology in its Cologuard® stool DNA-based colorectal cancer screening test.
  • After receiving a cease-and-desist letter from Exact Sciences regarding its patent infringement, Geneoscopy requested a reexamination of the '781 patent by the United States Patent and Trademark Office (USPTO) in May 2023.
  • Upon completion of the reexamination in October 2023, the USPTO rejected Geneoscopy's challenge, confirming the patentability of all claims of the '781 patent for Exact Sciences.

Lakewood-Amedex Announces Leadership Changes

Retrieved on: 
Wednesday, November 1, 2023

UNIVERSITY PARK, Fla., Nov. 1, 2023 /PRNewswire/ -- Lakewood-Amedex Inc., a privately held, clinical-stage pharmaceutical discovery and development company advancing a broad portfolio of first-in-class antimicrobial and antifungal therapeutics called Bisphosphocins™, today announced that Peter B. Corr, Ph.D., who has served as board chairman since 2020, was named Executive Chairman and will assume the strategic responsibilities of former CEO Steve Parkinson who left the company at the request of the Board. Dr. Corr is the Co-founder and Managing General Partner of Auven Therapeutics Management LLLP. He retired from Pfizer Inc. in 2006 where he was Senior Vice President for Science and Technology, in addition to leading worldwide pharmaceutical research and development for Pfizer. Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development and President, Pfizer Worldwide Development. His full CV is on the Lakewood-Amedex website https://lakewoodamedex.com/about-us/board/

Key Points: 
  • Dr. Corr is the Co-founder and Managing General Partner of Auven Therapeutics Management LLLP.
  • Previously, Dr. Corr served as Executive Vice President, Pfizer Global Research & Development and President, Pfizer Worldwide Development.
  • His full CV is on the Lakewood-Amedex website https://lakewoodamedex.com/about-us/board/
    The Company also announced leadership promotions in the organization for Thomas Balzer, M.D., Ph.D., Senior Vice President for Clinical Development, and Kelvin Cooper, Ph.D., Vice President of Research and Development.
  • We look forward to their continued contributions as we work to advance our Research and Clinical Development programs."

Stan Lapidus Joins Calviri's Scientific Advisory Board

Retrieved on: 
Monday, October 30, 2023

PHOENIX, Oct. 30, 2023 /PRNewswire/ -- Calviri, Inc.— a leading biotech developer of promising new vaccines and diagnostics against cancer - today announced that Stan Lapidus, the founder of Cytyc Corporation and EXACT Sciences, has been elected to join Calviri's Scientific Advisory Board.

Key Points: 
  • PHOENIX, Oct. 30, 2023 /PRNewswire/ -- Calviri, Inc.— a leading biotech developer of promising new vaccines and diagnostics against cancer - today announced that Stan Lapidus, the founder of Cytyc Corporation and EXACT Sciences, has been elected to join Calviri's Scientific Advisory Board.
  • Lapidus will bring decades of experience in medical invention and entrepreneurship, and a decades-long track record in the development and execution of platforms and screenings for multiple cancers.
  • ThinPrep has been shown to be 65% more effective than other tests at detecting cervical cancer and precancerous lesions.
  • "Stan is one of the leading experts on cancer diagnostics with a long and distinguished history in this area.

Next-Generation Cologuard® Test Demonstrates High Sensitivity and Specificity in Pivotal BLUE-C Study, Significantly Outperforming Fecal Immunochemical Testing (FIT) for Cancer and Precancer Detection

Retrieved on: 
Sunday, October 22, 2023

MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal BLUE-C trial showing the next-generation Cologuard® test met all study endpoints, demonstrating 94 percent sensitivity for colorectal cancer (CRC) at 91% specificity, during the American College of Gastroenterology (ACG) Annual Meeting 2023.[1] Additionally, results show the next-generation Cologuard test was significantly more likely to detect cancer or precancer than fecal immunochemical testing (FIT)* (94% vs 67% and 43% vs 23%, respectively).[1]  Finally, the next-generation Cologuard test demonstrated higher sensitivity for the most clinically significant form of advanced precancerous lesions (high-grade dysplasia at 75%) than FIT (47%).[1]    

Key Points: 
  • In addition to superiority over FIT in sensitivity for both colorectal cancer and advanced precancerous lesions, the next-generation Cologuard test demonstrated 91% specificity.1 The specificity for FIT was 95%.
  • [1,3] For patients with a negative or non-neoplastic  findings on colonoscopy, specificity for the next-generation Cologuard test reached 93%.
  • "The findings indicate that the next-generation mt-sDNA test demonstrates even higher sensitivity for colorectal cancer screening (94%) and high-grade dysplasia (75%), compared with the current Cologuard test.
  • These findings suggest that, if FDA approved, the mt-sDNA test will be a valuable option in providing non-invasive colorectal cancer screening."

Terry Crews and His Creative Company Super Serious Join Ryan Reynolds’ Maximum Effort and the Colorectal Cancer Alliance to ‘LEAD FROM BEHIND’

Retrieved on: 
Tuesday, July 25, 2023

The nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance) is reteaming with Ryan Reynolds’ creative agency, Maximum Effort, to reignite LEAD FROM BEHIND, featuring Terry Crews to kick-off the effort.

Key Points: 
  • The nation’s leading nonprofit dedicated to colon cancer, the Colorectal Cancer Alliance (Alliance) is reteaming with Ryan Reynolds’ creative agency, Maximum Effort, to reignite LEAD FROM BEHIND, featuring Terry Crews to kick-off the effort.
  • Colon cancer is the second deadliest cancer in the U.S., yet it is highly preventable with timely screening.
  • “I’ve partnered with the Colorectal Cancer Alliance and LEAD FROM BEHIND because together we can prevent unnecessary suffering from The Preventable Cancer,” said Terry Crews.
  • That’s why colon cancer is The Preventable Cancer,” said Michael Sapienza, CEO of the Colorectal Cancer Alliance.

Next-generation Cologuard Test Demonstrates 94 Percent Sensitivity for Colorectal Cancer at 91 Percent Specificity, Raising the Bar in Non-invasive Screening

Retrieved on: 
Tuesday, June 20, 2023

MADISON, Wis., June 20, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced positive top-line results from the pivotal BLUE-C study. The results show that next-generation Cologuard® met all study endpoints and improved every top-line metric, including a 30 percent lower false positive rate, when compared to DeeP-C, the FDA registrational trial for Cologuard.

Key Points: 
  • Note: specificity including non-advanced findings includes colonoscopy results that were negative for cancer or advanced precancer upon histopathological review; specificity including no findings includes no findings on colonoscopy and no histopathological review; high-grade dysplasia includes carcinoma in situ and stage 0 cancer
    "Cologuard is a groundbreaking innovation in non-invasive cancer detection.
  • Next-generation Cologuard will set a new performance standard," said Kevin Conroy, chairman and CEO of Exact Sciences.
  • "We are harnessing deep scientific insights, advanced technology, and over a decade of research and development to detect colorectal cancer with greater sensitivity and significantly improve the false positive rate.
  • Once approved, next-generation Cologuard will meaningfully enhance the patient experience, and it comes at a critical time – when there are 60 million Americans not up to date with screening."

Exact Sciences Presents New Long-Term Patient Outcomes in Multi-Cancer Early Detection and Breast Cancer Recurrence Testing at ASCO® 2023

Retrieved on: 
Friday, May 26, 2023

"These first-ever, long-term MCED follow-up data confirm Exact Sciences' approach to detecting multiple cancers at earlier stages of disease, and show that early detection enables successful treatment and long-term freedom from cancer in patients," said Tom Beer, MD, Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences.

Key Points: 
  • "These first-ever, long-term MCED follow-up data confirm Exact Sciences' approach to detecting multiple cancers at earlier stages of disease, and show that early detection enables successful treatment and long-term freedom from cancer in patients," said Tom Beer, MD, Chief Medical Officer, Multi-Cancer Early Detection, Exact Sciences.
  • In addition, Exact Sciences will present a new, long-term Surveillance, Epidemiology, and End Results (SEER) analysis showing that the Oncotype DX Breast Recurrence Score® test is prognostic for breast cancer-specific mortality (BCSM) in patients with invasive ductal carcinoma (IDC) and invasive lobular breast cancer (ILC).
  • The Oncotype DX Breast Recurrence Score test is a prognostic genomic test designed to predict the likelihood of disease recurrence and chemotherapy benefit for patients with early-stage breast cancer, which Exact Sciences clinically validated in the TAILORx and RxPONDER trials.
  • Abstract #e22508 (E-pub): A flexible quantitative framework to assess the potential contribution of early cancer detection to improved cancer survival.

EXACT SCIENCES AWARDS GRANTS TO 18 ORGANIZATIONS FOCUSED ON INCREASING COLORECTAL CANCER SCREENINGS

Retrieved on: 
Wednesday, May 17, 2023

Grant recipients are committed to improving uptake of colorectal cancer (CRC) screening and supporting affordable pathways to follow-up care for people who are medically underserved.

Key Points: 
  • Grant recipients are committed to improving uptake of colorectal cancer (CRC) screening and supporting affordable pathways to follow-up care for people who are medically underserved.
  • "Awareness and access are critical to increasing screenings, and Exact Sciences is honored to support these organizations that are driving screening uptake and addressing inequities within their communities."
  • Exact Sciences developed Cologuard®, the first and only FDA-approved, noninvasive, multi-target, stool-based DNA screening test that people can use at home.
  • The organization plans to implement a cancer awareness program focused on reducing CRC morbidity and mortality for people of color.